Denali Advisors LLC Sells 9,300 Shares of Gilead Sciences, Inc. (GILD)

Denali Advisors LLC lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 139,577 shares of the biopharmaceutical company’s stock after selling 9,300 shares during the period. Gilead Sciences comprises about 1.9% of Denali Advisors LLC’s portfolio, making the stock its 19th biggest position. Denali Advisors LLC’s holdings in Gilead Sciences were worth $11,309,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Penserra Capital Management LLC lifted its stake in shares of Gilead Sciences by 9.5% in the 1st quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 144 shares during the period. Migdal Insurance & Financial Holdings Ltd. acquired a new position in shares of Gilead Sciences in the 2nd quarter valued at about $147,000. Harel Insurance Investments & Financial Services Ltd. lifted its stake in shares of Gilead Sciences by 29.3% in the 2nd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,120 shares of the biopharmaceutical company’s stock valued at $150,000 after purchasing an additional 480 shares during the period. Rowland & Co. Investment Counsel ADV acquired a new position in shares of Gilead Sciences in the 2nd quarter valued at about $153,000. Finally, Capstone Investment Advisors Netherlands B.V. acquired a new position in shares of Gilead Sciences in the 2nd quarter valued at about $172,000. Hedge funds and other institutional investors own 75.94% of the company’s stock.

A number of research analysts recently weighed in on GILD shares. Mizuho reaffirmed a “buy” rating on shares of Gilead Sciences in a research note on Friday, September 29th. Berenberg Bank set a $96.00 price target on Gilead Sciences and gave the stock a “buy” rating in a research note on Thursday, October 19th. William Blair reaffirmed a “buy” rating on shares of Gilead Sciences in a research note on Thursday, October 19th. JPMorgan Chase & Co. set a $85.00 price target on Gilead Sciences and gave the stock a “buy” rating in a research note on Wednesday, October 25th. Finally, Maxim Group raised Gilead Sciences from a “hold” rating to a “buy” rating and upped their price target for the stock from $73.67 to $94.00 in a research note on Thursday, November 30th. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Gilead Sciences has an average rating of “Buy” and an average price target of $85.03.

In other Gilead Sciences news, insider John C. Martin sold 50,000 shares of the stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $73.62, for a total transaction of $3,681,000.00. Following the sale, the insider now owns 3,046,766 shares in the company, valued at $224,302,912.92. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Gregg H. Alton sold 15,000 shares of the stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $74.82, for a total value of $1,122,300.00. Following the sale, the executive vice president now owns 77,363 shares in the company, valued at approximately $5,788,299.66. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 461,666 shares of company stock worth $34,072,567. Company insiders own 1.30% of the company’s stock.

Shares of Gilead Sciences, Inc. (NASDAQ GILD) traded down $0.04 during midday trading on Friday, reaching $79.02. The company’s stock had a trading volume of 6,366,180 shares, compared to its average volume of 8,150,000. Gilead Sciences, Inc. has a 1-year low of $63.76 and a 1-year high of $86.27. The company has a market capitalization of $103,190.00, a price-to-earnings ratio of 8.99, a price-to-earnings-growth ratio of -1.58 and a beta of 1.13. The company has a current ratio of 3.68, a quick ratio of 3.56 and a debt-to-equity ratio of 1.10.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, beating the consensus estimate of $2.13 by $0.14. The business had revenue of $6.51 billion during the quarter, compared to analyst estimates of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. Gilead Sciences’s revenue was down 13.2% compared to the same quarter last year. During the same period in the prior year, the company earned $2.75 earnings per share. equities research analysts anticipate that Gilead Sciences, Inc. will post 8.53 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Thursday, December 28th. Shareholders of record on Friday, December 15th were given a dividend of $0.52 per share. The ex-dividend date was Thursday, December 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.63%. Gilead Sciences’s dividend payout ratio is currently 23.66%.

ILLEGAL ACTIVITY NOTICE: “Denali Advisors LLC Sells 9,300 Shares of Gilead Sciences, Inc. (GILD)” was published by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this story on another domain, it was stolen and republished in violation of United States and international copyright law. The original version of this story can be accessed at https://stocknewstimes.com/2018/01/12/denali-advisors-llc-has-11-31-million-position-in-gilead-sciences-inc-gild.html.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply